PlainPharmaWatch

CMS Open Payments · Program Year 2024

Medimetriks Pharmaceuticals, Inc.

Medimetriks Pharmaceuticals, Inc. reported $35,928.14 across General Payments, Research, and Ownership to 866 physicians and teaching hospitals across 866 transactions.

See the rankings → How this is sourced
$35.9K
All-tracks total
866
Transactions
866
Recipients
−$32.3K
General Payments vs PY2023

Medimetriks Pharmaceuticals, Inc. reported $35,928.14 across all CMS Open Payments tracks (General + Research + Ownership) to 866 physicians and teaching hospitals in Program Year 2024 - ranking #1430 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $35,928.14, averaging $41.49 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer medimetriks-pharmaceuticals-inc Medimetriks Pharmaceuticals, Inc.

$35.9K · #1430/1,925 · 0.0% industry · PY2024

  • TOT $35.9K
  • RANK #1430
  • SHARE 0.0%
  • TXN 866
  • RCP 866
  • CAT 2
  • GEN $35.9K
  • ΔGEN −$32.3K
  • TOP1 5.6%
  • PY 2024

Volume peers

Nearest volume peer: Den-Mat Holdings, LLC ($35.9K)

Diagnostic Green GmbH$36.0KSensible Medical Innovations…$36.0KMedimetriks Pharmaceuticals,…$35.9KDen-Mat Holdings, LLC$35.9KTherakos Healthcare LLC$35.7K
All-tracks payment totals near Medimetriks Pharmaceuticals, Inc. (CMS Open Payments PY2024)

Medimetriks Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Medimetriks Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $32.3K (−47.3%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: MEDIMETRIKS PHARMACEUTICALS, INC.PY2023: MEDIMETRIKS PHARMACEUTICALS, INC.PY2024: Medimetriks Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$68.2KPY2024$35.9K
PY2023
$68,224.34
PY2024
$35,928.14

What the Data Shows for Medimetriks Pharmaceuticals, Inc.

In Program Year 2024, Medimetriks Pharmaceuticals, Inc. reported $35,928.14 in payments to 866 physicians and teaching hospitals across 866 individual transactions, an average of $41.49 per transaction and $41.49 per recipient. That total places Medimetriks Pharmaceuticals, Inc. at rank #1430 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 2 general-payment categories charted below, "Food and Beverage" is the largest at $21.0K across 813 transactions, 58.4% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 2 types of general payments, Medimetriks Pharmaceuticals, Inc.'s largest category was "Food and Beverage" at $21.0K - 58.4% of General Payments.

How Medimetriks Pharmaceuticals, Inc. divides its payments

How the reported total splits across payment categories

1. Food and Beverage$21.0K2. Consulting Fee$14.9K
Payment Type Amount Transactions
Food and Beverage $21.0K 813
Consulting Fee $14.9K 53

Recipient Concentration in General Payments

The five largest recipient relationships account for $6,803.42 (18.9%) of $35,928.14 in this company's General Payments records across 271 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Medimetriks Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Denton Paul Edwin Mow$2.0KGary Byron Slaughter$1.5KJason Green$1.4KJacqueline Ellen Leyrer$974.85Laurel Castano$928.38
  1. 1

    Denton Paul Edwin Mow

    $1,996.90 across 57 reported transactions

  2. 2

    Gary Byron Slaughter

    $1,503.29 across 34 reported transactions

  3. 3

    Jason Green

    $1,400.00 across 4 reported transactions

  4. 4

    Jacqueline Ellen Leyrer

    $974.85 across 28 reported transactions

  5. 5

    Laurel Castano

    $928.38 across 39 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Medimetriks Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Medimetriks Pharmaceuticals, Inc..

Midmark Corporation

HHI 152

Smith+Nephew, Inc.

HHI 151

Dendreon Pharmaceuticals LLC

HHI 150

Spineart USA Inc

HHI 154

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Medimetriks Pharmaceuticals, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Medimetriks Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.